Treatable metabolic and inflammatory abnormalities in Post COVID Syndrome (PCS) define the transcriptomic basis for persistent symptoms: Lessons from CIRS

Main Article Content

Ryan Shoemaker S. McMahon A. Heyman D. Lark M. van der Westhuizen J. Ryan

Abstract

Within three months of the onset of acute SARS-CoV-2 (COVID-19) infections, new and persistent symptoms were noted in survivors. While the world’s medical and research communities focus on saving lives following COVID-19 infection, a relentless march of new cases of Post-COVID Syndrome (PCS) continues to spread around the globe as a second COVID-related pandemic. Efforts to define the physiology of PCS, a multisystem, multi-symptom illness, continue without success, in part due to the markedly different case presentations.


 


Using a transcriptomic assessment of persistently ill cases of PCS, we show the presence of (i) molecular hypometabolism (MHM) and proliferative physiology; (ii) elevated levels of ribosomal stress responses and a concomitant increase in gene activation of TGFBR; and (iii) common co-expression of CD14 and Toll Receptor 4, correlated to exposure of amplified microbial growth in a water-damaged environment, specifically Actinobacteria and endotoxin, respectively, compared to recovered PCS cases. Total symptom scores and visual contrast sensitivity (VCS) results showed statistically significant differences.


 


The data reported here supports the concept that PCS occurs in patients with additional environmental exposures and enhanced TGF signaling. In a strikingly similar condition called Chronic Inflammatory Response Syndrome (CIRS), named in 2010, the transcriptomic abnormalities were identified to respond to treatment with FDA-cleared medications, with salutary benefits for affected cases. Though sparsely reported, PCS cases share proteomic findings with CIRS. While additional studies are indicated, a new approach to the treatment of PCS is suggested.

Downloads

Download data is not yet available.

Article Details

How to Cite
SHOEMAKER, Ryan et al. Treatable metabolic and inflammatory abnormalities in Post COVID Syndrome (PCS) define the transcriptomic basis for persistent symptoms: Lessons from CIRS. Medical Research Archives, [S.l.], v. 9, n. 7, july 2021. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2493>. Date accessed: 19 may 2022. doi: https://doi.org/10.18103/mra.v9i7.2493.
Section
Research Articles

References

1. Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduction Targeted Therapy 2020; 5:84.0
2. Aydemir M, Aydemir H, Korkmaz E, Budak M, Cekin N, Pinarbasi E. Computationally predicted SARS-COV-2 encoded microRNAs target NFKB, JAK/STAT and TGFB signaling pathways. Gene Reports 2020; 22:101012.
3. Yousefi H, Poursheikhani A, Bahmanpour Z, Vatanmakanian M, Taheri M, Mashouri L, Alahari S. SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach. Biomedicine & Pharmacotherapy 2020; 130: 110548.
4. https://abcchicago.com/covid-symptoms-19-coronavirus-signs-and/6337918. Goudie C, Markoff B, Tressel C, Weidner R. 2020 Coronavirus symptoms: Mysterious, scary symptoms persist long after initial COVID-19 infection.
5. Townsend L, Dyer A, Jones K, Dunne J, Mooney A, Gaffney F, O’Connor L, Leavy D, Brien K, Dowds J, Sugrue J, Hopkins D, Cheallaigh C, Nadarajan P, McLaughlin A, Bourke N, Bergin C, O’Farrelly C, Bannan C, Conlon N. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 2020; 15: e0240784.
6. Shoemaker R, Johnson K, Jim L, Berry Y, Dooley M, Ryan J, McMahon S. Diagnostic process for chronic inflammatory response syndrome (CIRS): A consensus statement report of the consensus committee of Surviving Mold. Internal Medicine Review 2018; 4: 1-47.
7. Ryan J, Shoemaker R. RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal polypeptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing. Med Rev Arch 2016; 4(7): 1-11.
8. Shoemaker R, House D, Ryan J. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health 2013; 5(3): 396-401.
9. Shoemaker R, McMahon S, Ryan J., et al. Intranasal VIP safely restores atrophic grey matter nuclei in patients with CIRS.IMR, 2017; 3:1-14.
10. Shoemaker R. Residential and Recreational Acquisition of Possible Estuarine Associated Syndrome: A New approach to Successful Diagnosis and Therapy, Environmental Health Perspectives, Special CDC Pfiesteria Supplement, 2001; 109S5; 791-796.
11. Shoemaker R, House D. SBS and exposure to water damaged buildings: time series study, clinical trial and mechanisms; Neurotoxicology and Teratology 2006; 28: 573-588.
12. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after COVID-1. JAMA 2020; 324:603-5.
13. Taquet M, Geddes J, Husain M, Luciano S, Harrison P. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021; doi.org/10.1016/s2215-0366
14. Staven K, Ghanima W, Olsen M, Gilboe H, Einvok G. Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: A population-based study. Int. J. Environ. Res. Public Health 2021; 18: doi.org/10.3390
15. Borst B, Peters J, Brink M, Schoon Y, Bleeker C, Schers H, van Hees H, van Helvoort H, van den Boogaard M, van der Hoeven H, Reijers M, Prokop M, Vercoulen J, van den Heuvel M. Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis 2020; doi: 10.1093/cid/ciaa1750.
16. Mo X, Jian W, Su Z. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020; 55: 2001217.
17. Vitiello A, Pelliccia C, Ferrara F. COVID-19 patients with pulmonary fibrotic tissue: clinical pharmacological rationale of antifibrotic therapy. Comprehensive Clinical Medicine 2020; doi.org/10.1007/s42399-020-00487-7.
18. Shaw B, Daskareh M, Gholamrezanezhad A. The lingering manifestations of COVID-19 during and after convalescence: update on long-term pulmonary consequences of coronavirus disease 2019 (COVID-19). Italian Society of Medical Radiology 2020; doi.org/10.1007/s11547-020-01295-8.
19. Huang C, Huang L, Wang Y, Li X, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Li y, Li C, Yong L, Xie W, Cui D, Shang L, Gan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Zhang D, Caot B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 2230-32.
20. Jain R, Ramaswamy S, Harilal D, Uddin M, Loney T, Nowotny N, Alsuwaidi H, Varghese R, Deesi Z, Alkhajeh A, Khansaheb H, Alsheikh-Ali A, Tayoun A. Host transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomes. Computational and Structural Biotechnology Journal 2021; 19: 153-160.
21. Shoemaker R. Metabolism, molecular hypometabolism and inflammation: Complications of proliferative physiology include metabolic acidosis, pulmonary hypertension, T reg cell deficiency, insulin resistance and neuronal injury. Trends Diabetes Metab 2021; 3: 1-15.
22. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, Guo D, Hu W, Yang J, Tang Z, Wu H, Lin Y, Zhang M, Zhang Q, Shie M, Liu Y, Zhou Y, Lan K, Chen Y. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging and Microbes & Infections 2020; 9: 761-770.
23. Zhang C, Wu Z, Li J, Tan K, Yang W, Zhao H, Wang G. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19. J Med Virol 2021; 3: 1378-1386.
24. Murthy K, Sivashanmugam K, Kandasamy M, Subbiah R, Ravikumar V. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-B signaling in COVID-19 survivors. Life Sciences 2021; 266:118883.
25. Shoemaker R, Neil V, Heyman A, van der Westhuizen M, McMahon S, Lark D. Newer molecular methods bring new insights into human-and-building health risk assessments from water-damaged buildings: Defining exposure and reactivity, the two sides of causation of CIRS-WDB illness. Medical Research Archives 2021; 9:1-36.
26. Sadeghi A, Tahmasebi S, Mahmood A, Kuznetsova M, Valizadeh H, Taghizadieh A, Nazemiyeh M, Aghebati-Maleki L, Jadidi-Niaragh F, Abbaspour-Aghdam S, Roshangar L, Mikaeili H, Ahmadi M. Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. J Cell Physiol 2021; 236: 2829-2839.
27. Allen J, Ibrahim A. Indoor air changes and potential implications for SARS-CoV-2 transmission. JAMA. Published online April 16, 2021; doi:10.1001/jama.2021.5053.